Erlotinib 25 mg/1 (Erlotinib TABLET, FILM COATED) 25 mg/1

Erlotinib 25 mg tablets are a medication used to treat certain types of cancer. This oral treatment is designed to target specific proteins involved in cancer cell growth. Learn more about Erlotinib and its uses.

Strength

25 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BOTTLE (0093-7662-56)

Manufacturer / TM Owner

Teva Pharmaceuticals USA, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Erlotinib is primarily used in the treatment of non-small cell lung cancer and pancreatic cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which can help slow down the growth and spread of cancer cells. This medication is often prescribed as part of a broader cancer treatment plan.

Side Effects

Common effects of Erlotinib may include skin rash, diarrhea, and fatigue. Some users may also experience appetite loss or mild nausea. These effects can vary in severity and duration, depending on individual factors.

Precautions & Warnings

Erlotinib should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by your healthcare professional. Always inform your healthcare provider about any other medications you are taking.

Avoid Interactions

Erlotinib may interact with certain medications, including those that are metabolized by the liver's cytochrome P450 enzymes. It is advisable to avoid grapefruit and grapefruit juice, as they can affect the metabolism of Erlotinib. Always consult your healthcare provider before starting any new medication.

Frequently Asked Questions

Erlotinib is used to treat certain types of cancer, including non-small cell lung cancer and pancreatic cancer.

Erlotinib is typically taken orally, with or without food, as directed by a healthcare professional.

Common side effects may include skin rash, diarrhea, fatigue, and appetite loss.

Erlotinib may interact with certain medications, so it is important to consult a healthcare provider before combining it with other drugs.

The safety of Erlotinib for long-term use should be discussed with a healthcare professional, who can provide guidance based on individual health conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.